Year archive

Lytix Biopharma AS — 2025 filings

All 45 regulatory filings released by Lytix Biopharma AS (LYTIX) in 2025, sourced directly from the official regulator.

45 Filings

2025 Period

2025 filings (45)

Filing	Released	Lang
LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - Attachment: Lytix - Øystein Rekdal - Mandatory notification of trade.pdf Director's Dealing	2025-12-11	English
LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER Director's Dealing	2025-12-11	English
Lytix Biopharma: Invitation to Q3 2025 Results Presentation - Attachment: Lytix Biopharma - Invitation to Q3 Presentation.pdf Report Publication Announcement	2025-11-14	English
Lytix Biopharma: Invitation to Q3 2025 Results Presentation Report Publication Announcement	2025-11-14	English
Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital - Attachment: NeoLIPA Interim Data - Pre Regulatory Filings	2025-11-11	English
Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhospitalet - Attachment: NeoLIPA Interim Data - Press release - Norsk - Final.pdf Regulatory Filings	2025-11-11	Norwegian
Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital Regulatory Filings	2025-11-11	English
Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhospitalet Regulatory Filings	2025-11-11	Norwegian
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide - Attachment: SITC 2025 - Poster - Ruxotemitide (VP-31 Regulatory Filings	2025-11-10	English
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide - Attachment: Lytix SITC Press Release FINAL.pdf Regulatory Filings	2025-11-10	English
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide Regulatory Filings	2025-11-10	English
Financial calendar Report Publication Announcement	2025-10-10	English
Finansiell kalender Report Publication Announcement	2025-10-10	Norwegian
Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 - Attachment: Lytix Biopharma - Verrica to pres Regulatory Filings	2025-10-08	English
Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 Regulatory Filings	2025-10-08	English
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization - Attachment: Lytix Biopharma Q2 2025_Press Release - Final.pdf Earnings Release H1 2025	2025-08-28	English
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization - Attachment: 2025-Q2 - Lytix Biopharma - Quarterly Presentation - Investor Presentation	2025-08-28	English
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization - Attachment: 2025-H1 - Lytix Biopharma - Interim Report - IFRS - Interim / Quarterly Report H1 2025	2025-08-28	English
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization Earnings Release H1 2025	2025-08-28	English
Lytix Biopharma: Invitation to Q2 2025 Results Presentation - Attachment: Lytix Biopharma - Invitation to Q2 Presentation.pdf Report Publication Announcement	2025-08-21	English
Lytix Biopharma: Invitation to Q2 2025 Results Presentation Report Publication Announcement	2025-08-21	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Director's Dealing	2025-05-21	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Director's Dealing	2025-05-21	English
Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress Investor Presentation	2025-05-15	English
Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress Earnings Release Q1 2025	2025-05-15	English
Lytix Biopharma: Invitation to Q1 2025 Results Presentation Report Publication Announcement	2025-05-09	English
Lytix Biopharma: Invitation to Q1 2025 Results Presentation Report Publication Announcement	2025-05-09	English
Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New Board of Directors AGM Information	2025-04-29	Norwegian
Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New Board of Directors AGM Information	2025-04-29	English
Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair AGM Information	2025-04-22	English
Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair Remuneration Information	2025-04-22	English
Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair AGM Information	2025-04-22	English
Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 AGM Information	2025-04-10	Norwegian
Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 AGM Information	2025-04-10	English
Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 AGM Information	2025-04-10	English
Lytix Biopharma AS: Annual Report for 2024 Annual Report FY 2024	2025-04-10	English
Lytix Biopharma AS: Annual Report for 2024 Report Publication Announcement	2025-04-10	English
Lytix Biopharma AS: Annual Report for 2024 Report Publication Announcement	2025-04-10	English
Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 Interim / Quarterly Report Q4 2024	2025-02-13	English
Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 Earnings Release Q4 2024	2025-02-13	English
Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 Earnings Release Q4 2024	2025-02-13	English
Lytix Biopharma receives Notice of Allowance for U.S. patent application covering its LTX-315 clinical program Regulatory Filings	2025-02-12	English
Lytix Biopharma: Invitation to Q4 2024 Results Presentation Report Publication Announcement	2025-02-07	English
Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference Regulatory Filings	2025-01-22	English
Lytix Biopharma AS - New share capital registered Share Issue/Capital Change	2025-01-15	English